US20170209470A1 - Use of neridronic acid or of its salt for the treatment of osteoarthrosis - Google Patents

Use of neridronic acid or of its salt for the treatment of osteoarthrosis Download PDF

Info

Publication number
US20170209470A1
US20170209470A1 US15/514,651 US201515514651A US2017209470A1 US 20170209470 A1 US20170209470 A1 US 20170209470A1 US 201515514651 A US201515514651 A US 201515514651A US 2017209470 A1 US2017209470 A1 US 2017209470A1
Authority
US
United States
Prior art keywords
salt
neridronic acid
sodium
treatment
osteoarthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/514,651
Other languages
English (en)
Inventor
Massimo Varenna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abiogen Pharma SRL
Original Assignee
Abiogen Pharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51904075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20170209470(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abiogen Pharma SRL filed Critical Abiogen Pharma SRL
Assigned to ABIOGEN PHARMA SPA reassignment ABIOGEN PHARMA SPA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VARENNA, MASSIMO
Publication of US20170209470A1 publication Critical patent/US20170209470A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to the use of neridronic acid or a salt thereof in the treatment of osteoarthritis.
  • neridronic acid or a salt thereof has been shown to be able to reduce significantly the symptoms of osteoarthritis, such as pain and physical disabilities, as well as subchondral bone marrow lesions underlying the onset of such symptoms.
  • Osteoarthritis is, along with hypertension, the disease with the highest prevalence in the world over fifty years old population and is the most common cause of chronic disability. Given the epidemiological importance of said disease, to date there are no recognized effective therapeutic strategies capable of modifying the disease course, slowing/stopping the anatomical progression of joint damage.
  • the therapeutic objectives which can be currently pursued are therefore only aimed at reducing painful symptoms and functional deficits associated therewith.
  • the non-pharmacological approach understood as joint saving strategy (functional limitation and reduction of body weight on bearing joints) and which may involve the use of specific tools (braces, splints, Canadian sticks) and the kinesitherapic approach (maintaining the muscle tone/trophism and joint mobility through specific rehabilitative exercises) turns out to be the most unanimous therapeutic strategy, despite the clear limitations of a modest impact on pain symptoms.
  • other instrumental physical therapies such as the local application of radiation or ultrasonographic waves does not have an unanimous utility and above all, is poorly effective at the level of joint sites frequently affected by arthritis, such as the large joints of the lower limb (hip and knee).
  • the surgical approach is solely aimed at a preventive (correction of anatomic defects which cause an altered load) or radical strategy, such as prosthetic joint replacement, where possible, of joints severely anatomically damaged.
  • the pharmacological strategy is the strategy usually and widely used in the management of arthritis pain.
  • the need for a chronic or in any case prolonged therapy, the old age of the patient and thus the frequent presence of other diseases and relevant treatments represent the obstacles which the clinician must systematically deal with.
  • the most conservative approach refers to the use of minor analgesics such as paracetamol, which usually shows a fair risk-benefit profile when used at the dosages usually prescribed for treating chronic pain symptoms, i.e. minor pain experienced daily by the patient, while it is only modestly effective in treating middle/high intensity arthritic pain.
  • opioid i.e. with a stronger analgesic effect
  • opioid i.e. with a stronger analgesic effect
  • NSAIDs nonsteroidal anti-inflammatory drugs
  • BPs bisphosphonates
  • BPs are a class of drugs widely and specifically used in the treatment of postmenopausal osteoporosis and other skeletal disorders characterized by an altered bone metabolism.
  • Spector T D et al. point out that the preliminary clinical data obtained on the effect of risedronate one year after treatment were not then replicated and confirmed in the subsequent study extended to two years of treatment.
  • Said object has been achieved by using neridronic acid or a salt thereof in the treatment of osteoarthritis as stated in claim 1 .
  • neridronic acid or a salt thereof has been shown to be able to reduce significantly the symptoms of osteoarthritis, such as pain and disabilities, as well as subchondral bone marrow lesions underlying the onset of such symptoms.
  • the present invention relates to a pharmaceutical composition to be administered intravenously, comprising said neridronic acid or a salt thereof for use in the treatment of osteoarthritis, and to pharmaceutically acceptable vehicles for intravenous administration.
  • the present invention relates to a vial or bottle for intravenous administration comprising neridronic acid or a salt thereof for use in the treatment of osteoarthritis.
  • the present invention relates to a pharmaceutical composition to be administered intramuscularly, comprising said neridronic acid or a salt thereof for use in the treatment of osteoarthritis, and to pharmaceutically acceptable vehicles for intramuscular administration.
  • the present invention relates to a vial or bottle for intramuscular administration comprising neridronic acid or a salt thereof for use in the treatment of osteoarthritis.
  • FIG. 1 shows the apportionment of patients recruited for the study of Example 1
  • FIG. 2 shows the trend of the VAS parameter during the 60 days following the beginning of treatment of patients according to the study of Example 1.
  • the invention thus relates to neridronic acid or a salt thereof for use in the treatment of osteoarthritis (briefly, “OA”).
  • neridronic acid or a salt thereof has been shown to be able to reduce significantly the symptoms of osteoarthritis, such as pain and physical disabilities, as well as the size of subchondral bone marrow lesions.
  • neridronic acid or a salt thereof has proved to be able to successfully treat osteoarthritis by relieving mild, moderate or severe symptoms ascribable thereto, in particular moderate or severe symptoms.
  • Neridronic acid or a salt thereof has been shown to be able to successfully treat mild, moderate or severe pain symptoms in patients suffering from osteoarthritis, particularly OA of the hip, knee or hand, especially OA of the knee.
  • neridronic acid or a salt thereof has shown to be able to successfully treat osteoarthritis by relieving joint stiffness and improving mobility and physical functionality.
  • neridronic acid or a salt thereof has been shown to be able to successfully treat joint stiffness, by improving mobility and physical functionality in patients suffering from OA of the hip, knee or hand, especially OA of the knee.
  • neridronic acid or a salt thereof has been shown to reduce significantly pain intensity in patients with OA, as well as joint stiffness, and advantageously improve mobility and physical functionality even after more than 50 days since the end of treatment.
  • Neridronic acid or a salt thereof has further proved to be able to treat pain in patients with OA during acute painful relieveee.
  • neridronic acid or a salt thereof has proved to be able to reduce the sizes and extents of bone marrow lesions associated with arthritis pain symptoms.
  • neridronic acid or a salt thereof can successfully improve the pattern of subchondral bone marrow lesions detectable by nuclear magnetic resonance (NMR).
  • the term “neridronic acid or a salt thereof” is understood to include all polymorphic forms, both amorphous and crystalline, as well as co-crystalline and anhydrous, hydrated and solvate forms.
  • said neridronic acid is in the form of a salt.
  • Said neridronic acid salt is alkaline or alkaline-earthy neridronate salt, such as sodium neridronate or potassium neridronate, quaternary ammonium salt of neridronate or a mixture thereof.
  • said neridronic acid salt is sodium neridronate.
  • Neridronic acid or a salt thereof is to be preferably administered at a dosage of 10-500 mg.
  • Said neridronic acid or a salt thereof can be administered orally, intramuscularly, intravenously, intraarticularly, transdermally, subcutaneously or topically.
  • said neridronic acid or a salt thereof is to be administered intravenously.
  • Neridronic acid or a salt thereof is to be administered intravenously, preferably at a dosage of 25-400 mg. More preferably, said neridronic acid or a salt thereof is to be administered at least 2 times, with at least 1 day between an administration and a subsequent one.
  • day means a period of 24 ⁇ 2 hours.
  • said neridronic acid or a salt thereof can be used according to dosing regimens comprising daily administrations, alternate-day administrations, or administrations every at least two or three days and beyond.
  • said neridronic acid or a salt thereof is to be administered intravenously at a dosage of 50-200 mg, at least 2 times over a period of 5-15 days, with at least 1 day between an administration and a subsequent one.
  • said neridronic acid or a salt thereof is to be administered intravenously at a dosage of 50-200 mg, at least 3 times over a period of 5-15 days, with at least 2 days between an administration and a subsequent one.
  • said neridronic acid or a salt thereof is to be administered intravenously at a dosage of 70-150 mg, 4 times over a period of 8-12 days, with 2 days between an administration and a subsequent one.
  • said neridronic acid or a salt thereof is to be administered intravenously at a dosage of 70-150 mg, 4 times over a period of 8-12 days, with 3 days between an administration and a subsequent one.
  • said neridronic acid or a salt thereof is to be administered intravenously at a dosage of 90-110 mg, 4 times over a period of 10 days, with 3 days between an administration and a subsequent one.
  • said neridronic acid is in the form of sodium salt (sodium neridronate) to be administered intravenously at a dosage of 90-110 mg, 4 times over a period of 10 days, with 3 days between an administration and a subsequent one.
  • said neridronic acid in the form of sodium salt is to be administered intravenously at a dosage of 100 mg of neridronic acid, 4 times over a period of 10 days, with 3 days between an administration and a subsequent one. In this way, the intravenous administration can be carried out on days 1, 4, 7 and 10 of treatment.
  • the results of the randomized controlled study demonstrated that sodium neridronate can be used effectively for treating patients with OA.
  • the results of this study demonstrated that sodium neridronate can be used effectively to reduce the mild, moderate or severe pain symptoms, and even more specifically moderate or severe symptoms, in patients with OA.
  • sodium neridronate can be used effectively to reduce pain symptoms in patients with OA having basal VAS (greater than or equal to) 30 mm.
  • a course of sodium neridronate administered intravenously can be used effectively to treat patients with OA, and in particular to reduce mild, moderate or severe pain symptoms in patients with OA.
  • sodium neridronate can be used effectively for treating patients with OA undergoing acute painful remplisees, thus reducing the extent of bone marrow lesions.
  • said neridronic acid or a salt thereof is in the form of an aqueous solution of neridronic acid or a salt thereof.
  • Said aqueous solution is preferably isotonic or hypotonic, even more preferably hypotonic.
  • Said neridronic acid or a salt thereof is further preferably present as a unit dose comprising 1-10 ml of aqueous solution in a vial or bottle, preferably a glass vial or bottle.
  • said unit dose comprises 2, 5 or 8 ml of an aqueous solution in a vial or bottle.
  • said unit dose comprises 70-150 mg of neridronic acid or a salt thereof.
  • said unit dose comprises 100 mg of neridronic acid or comprises a salt thereof in an amount equivalent to 100 mg of neridronic acid.
  • the present invention also relates to a vial or bottle for intravenous administration comprising neridronic acid or a salt thereof for use in the treatment of osteoarthritis.
  • said vial or bottle comprises a unit dose of 70-150 mg of neridronic acid or a salt thereof.
  • said vial or bottle comprises 100 mg of neridronic acid or comprises a salt thereof in an amount equivalent to 100 mg of neridronic acid.
  • said vial or bottle is in a ready-to-use form.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising said neridronic acid or a salt thereof for use in the treatment of osteoarthritis, and pharmaceutically acceptable vehicles for the oral, intramuscular, intravenous, intra-articular, transdermal, sub-cutaneous or topical administration.
  • said pharmaceutical composition comprising said neridronic acid or a salt thereof, and pharmaceutically acceptable vehicles for the oral, intramuscular, intravenous, intra-articular, transdermal, sub-cutaneous or topical administration, is for use in the treatment of osteoarthritis of the hip, knee or hand, preferably it is for use in the treatment of osteoarthritis of the knee.
  • said pharmaceutical composition is to be administered intravenously and comprises said neridronic acid or a salt thereof for use in the treatment of osteoarthritis, and pharmaceutically acceptable vehicles for intravenous administration.
  • Pharmaceutically acceptable vehicles suitable for intravenous administration are for example, pH adjusters, isotonicity adjusters, stabilizers, chelating agents, preservatives and antioxidants.
  • Preferred pH adjusters are citric acid, sodium citrate, sodium acetate, boric acid, sodium borate, sodium bicarbonate, phosphoric acid and salts thereof, even more preferably citric acid and sodium citrate (citrate buffer) and sodium bicarbonate.
  • sodium chloride is preferred.
  • mannitol mannitol, dextran or mixtures thereof are preferred.
  • EDTA or a salt thereof, such as sodium EDTA, is preferred.
  • antioxidants sodium metabisulphite, potassium metabisulphite, sodium bisulphite, butylated hydroxy anisole (BHA), butylated hydroxy toluene (BHT), ascorbic acid and sodium ascorbate are preferred.
  • benzyl alcohol, methyl paraben and propyl paraben are preferred.
  • said pharmaceutical composition to be administered intravenously comprises sodium neridronate for use in the treatment of osteoarthritis, citrate buffer and sodium chloride.
  • said pharmaceutical composition to be administered intravenously comprises sodium neridronate for use in the treatment of osteoarthritis, sodium bicarbonate and sodium chloride.
  • said neridronic acid or a salt thereof is the only active ingredient present for use in the treatment of osteoarthritis.
  • said pharmaceutical composition to be administered intravenously consists of said neridronic acid or a salt thereof for use in the treatment of osteoarthritis, and pharmaceutically acceptable vehicles for intravenous administration.
  • the pharmaceutical composition is in the form of an aqueous solution.
  • Said aqueous solution is preferably isotonic or hypotonic, even more preferably hypotonic.
  • Said pharmaceutical composition is further preferably present as a unit dose comprising 1-10 ml of aqueous solution in a vial or bottle, preferably a glass vial or bottle.
  • said unit dose comprises 2, 5 or 8 ml of an aqueous solution in a vial or bottle.
  • said unit dose comprises 70-150 mg of neridronic acid or a salt thereof.
  • said unit dose comprises 100 mg of neridronic acid or comprises a salt thereof in an amount equivalent to 100 mg of neridronic acid.
  • the present invention therefore also relates to a vial or bottle for intravenous administration comprising neridronic acid or a salt thereof for use in the treatment of osteoarthritis.
  • said vial or bottle comprises a unit dose of 70-150 mg of neridronic acid or a salt thereof.
  • said vial or bottle comprises 100 mg of neridronic acid or comprises a salt thereof in an amount equivalent to 100 mg of neridronic acid.
  • said vial or bottle is in a ready-to-use form.
  • said neridronic acid or a salt thereof is sodium neridronate for use in the treatment of osteoarthritis.
  • said vial or bottle is for the intravenous administration of sodium neridronate for use in the treatment of osteoarthritis.
  • said neridronic acid or a salt thereof is to be administered intramuscularly.
  • Neridronic acid or a salt thereof is to be administered intramuscularly preferably at a dosage of 10-100 mg.
  • said neridronic acid or a salt thereof is to be administered intramuscularly at a dosage of 15-50 mg, more preferably at a dosage of 25 mg of neridronic acid or at an equivalent dosage of a salt thereof, preferably sodium neridronate.
  • said neridronic acid or a salt thereof is sodium neridronate to be administered intramuscularly at a dosage of 15-50 mg, 1 to 20 times over a period of 1-30 days.
  • said neridronic acid or a salt thereof is sodium neridronate to be administered intramuscularly at a dosage of 25 mg of neridronic acid, 1 to 16 times over a period of 1-16 days.
  • the present invention relates to a pharmaceutical composition to be administered intramuscularly and comprises said neridronic acid or a salt thereof for use in the treatment of osteoarthritis, and pharmaceutically acceptable vehicles for intramuscular administration.
  • Pharmaceutically acceptable vehicles suitable for intramuscular administration are for example, pH adjusters, isotonicity adjusters, stabilizers, chelating agents, preservatives and antioxidants.
  • Preferred pH adjusters are citric acid, sodium citrate, sodium acetate, boric acid, sodium borate, sodium bicarbonate, phosphoric acid and salts thereof, even more preferably citric acid and sodium citrate (citrate buffer) and sodium bicarbonate.
  • sodium chloride is preferred.
  • mannitol mannitol, dextran or mixtures thereof are preferred.
  • EDTA or a salt thereof, such as sodium EDTA, is preferred.
  • antioxidants sodium metabisulphite, potassium metabisulphite, sodium bisulphite, butylated hydroxy anisole (BHA), butylated hydroxy toluene (BHT), ascorbic acid and sodium ascorbate are preferred.
  • benzyl alcohol, methyl paraben and propyl paraben are preferred.
  • said pharmaceutical composition to be administered intramuscularly comprises sodium neridronate for use in the treatment of osteoarthritis, citrate buffer and sodium chloride.
  • said pharmaceutical composition to be administered intramuscularly comprises sodium neridronate for use in the treatment of osteoarthritis, sodium bicarbonate and sodium chloride.
  • said neridronic acid or a salt thereof is the only active ingredient present for use in the treatment of osteoarthritis.
  • said pharmaceutical composition to be administered intramuscularly consists of said neridronic acid or a salt thereof for use in the treatment of osteoarthritis, and pharmaceutically acceptable vehicles for intramuscular administration.
  • the pharmaceutical composition is in the form of an aqueous solution of neridronic acid or a salt thereof.
  • Said aqueous solution is preferably isotonic or hypotonic, even more preferably hypotonic.
  • Said pharmaceutical composition is further preferably present as a unit dose comprising 1-10 ml of aqueous solution in a vial or bottle, preferably a glass vial or bottle.
  • said unit dose comprises 2, 5 or 8 ml of an aqueous solution in a vial or bottle.
  • said unit dose comprises 10-100 mg of neridronic acid or a salt thereof.
  • said unit dose comprises 25 mg of neridronic acid or comprises a salt thereof in an amount equivalent to 25 mg of neridronic acid.
  • the present invention therefore also relates to a vial or bottle for intramuscular administration comprising neridronic acid or a salt thereof for use in the treatment of osteoarthritis.
  • said vial or bottle is in a ready-to-use form.
  • said neridronic acid or a salt thereof is sodium neridronate for use in the treatment of osteoarthritis.
  • said vial or bottle is for the intramuscular administration of sodium neridronate for use in the treatment of osteoarthritis.
  • said neridronic acid or a salt thereof is to be administered orally or sublingually.
  • the present invention relates to a pharmaceutical composition to be administered orally or sublingually and comprises said neridronic acid or a salt thereof for use in the treatment of osteoarthritis, and pharmaceutically acceptable vehicles for oral or sublingual administration.
  • Suitable pharmaceutically acceptable vehicles for oral or sublingual administration for example are natural starch, partially hydrolyzed starch, lactose, glucose, sucrose, mannitol, sorbitol, cellulose and derivatives thereof, microcrystalline cellulose and derivatives thereof, calcium phosphate, calcium carbonate, calcium sulfate, magnesium stearate, maltodextrin, gelatin, gum tragacanth, arabic gum, xanthan gum, talc, silica, colloidal silica, precipitated silica, magnesium silicates, aluminum silicates, sodium lauryl sulfate, magnesium lauryl sulfate, methacrylate copolymers, and mixtures thereof.
  • composition for oral or sublingual administration can be in the form of powder, capsule, tablet, mini-tablet, micro-tablet, granule, microgranule, pellet, multi-particulate or micronized particles.
  • it may be in liquid form, i.e. in solution, dispersion or suspension with suitable pharmaceutically acceptable solvents.
  • compositions described above can be prepared by using methods known in the art according to the route of administration.
  • a method for the treatment of osteoarthritis comprising the steps of:
  • said neridronic acid or a salt thereof can be in the form of an aqueous solution of neridronic acid or a salt thereof, as described above.
  • said neridronic acid or a salt thereof is provided as a unit dose comprising 1-10 ml of aqueous solution in a vial or bottle.
  • said method allows the pain symptoms of osteoarthritis to be relieved in a patient suffering from osteoarthritis.
  • step ii) the administration of a therapeutically effective amount of neridronic acid or a salt thereof to a patient suffering from osteoarthritis relieves mild, moderate or severe symptoms ascribable to osteoarthritis, in particular moderate or severe symptoms.
  • said administration relieves mild, moderate or severe pain symptoms in patients suffering from osteoarthritis of the hip, knee or hand, especially OA of the knee.
  • said administration effectively reduces pain symptoms in patients with OA having basal VAS (greater than or equal to) 30 mm.
  • said administration relieves joint stiffness and improves the mobility and physical functionality of the patient.
  • neridronic acid or a salt thereof reduces pain intensity in patients with OA, as well as joint stiffness and advantageously improves mobility and physical functionality even after more than 50 days since the end of treatment.
  • said administration relieves pain in patients with OA during acute painful liesees.
  • neridronic acid or a salt thereof reduces the size and extent of bone marrow lesions associated with pain symptoms caused by arthritis, particularly in the case of OA of the knee.
  • a method for the treatment of osteoarthritis comprising the steps of:
  • said pharmaceutical composition can be in the form of an aqueous solution of neridronic acid or a salt thereof, as described above.
  • said pharmaceutical composition is provided as a unit dose comprising 1-10 ml of aqueous solution of neridronic acid or a salt thereof in a vial or bottle.
  • said method allows the pain symptoms of osteoarthritis to be relieved in a patient suffering from osteoarthritis.
  • the administration of a therapeutically effective amount of a pharmaceutical composition of neridronic acid or a salt thereof to a patient suffering from osteoarthritis relieves mild, moderate or severe symptoms ascribable to osteoarthritis, in particular moderate or severe symptoms.
  • said administration relieves mild, moderate or severe pain symptoms in patients suffering from osteoarthritis of the hip, knee or hand, especially OA of the knee.
  • said administration effectively reduces pain symptoms in patients with OA having basal VAS (greater than or equal to) 30 mm.
  • said administration relieves joint stiffness and improves the mobility and physical functionality of the patient.
  • a pharmaceutical composition of neridronic acid or a salt thereof reduces pain intensity in patients with OA, as well as joint stiffness and advantageously improves mobility and physical functionality, even after more than 50 days since the end of treatment.
  • said administration relieves pain in patients with OA during acute painful liesees.
  • a pharmaceutical composition of neridronic acid or a salt thereof reduces the size and extent of bone marrow lesions associated with pain symptoms caused by arthritis, particularly in the case of OA of the knee.
  • the aim of this randomized, double-blind, placebo-controlled study was to assess the efficacy of intravenous neridronate in controlling pain in patients with acute painful knee osteoarthritis (OA).
  • OA acute painful knee osteoarthritis
  • knee OA fulfilling the American College of Rheumatology diagnostic criteria
  • a radiographic Kellgren-Lawrence grading score >2 in the tibiofemoral joint 3) a continuous knee pain by at least 2 weeks with an onset no longer than three months
  • Exclusion criteria were related to the presence of inflammatory or metabolic diseases; the presence of routine laboratory abnormalities (comprising calcemia, and glomerular filtration rate, which if altered are capable of increasing the risk of adverse events in patients treated with BPs intravenously); prior treatment with BPs; evidence of significant joint effusion through MRI scan, morphological alterations at the subchondral bone joint profile suggesting osteonecrosis and/or evidence of bursitis or tendonitis; onset of pain related to a specific traumatic event.
  • 58 patients out of 68 (85.3%) were taking or had taken drugs to control pain in the previous three months.
  • the patients were asked not to take any analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs) throughout the study period. All patients gave written consent.
  • the study was approved by the Ethics Committee of the hospital where the study was carried out.
  • Both sodium neridronate and placebo were diluted in 500 ml of saline isotonic solution and infused in the morning for over 2 hours. The treatment was administered every third day four times starting from day 1 (first infusion) and ending on day 10 (fourth infusion).
  • the MR protocol included: spin echo (SE) T1-weighted sequences (repetition time TR 580 ms, echo time TE 12 ms, number of signal averages 2, thickness 3.0 mm, intersection gap 0.5 mm) on sagittal, coronal and transverse planes; SE T2-weighted sequences (TR 4.000 ms, TE 30/100 ms, one signal acquired, thickness 3.0 mm, intersection gap 0.5 mm) on sagittal and transverse planes; PD-weighted sequence with fat/suppression (TR 2800 ms, TE 40 ms, one signal acquired, thickness 3.0 mm, intersection gap 0.5 mm) on coronal plane.
  • Subchondral BMLs were identified as areas of increase signal intensity on fat-suppressed T2-weighted images. Scores were assigned using the Whole-Organ MRI score for knee OA (WORMS) for bone marrow edema.
  • TO day 1
  • T1 day 10
  • T2 days later
  • WOMAC Western Ontario and MacMaster Universities Osteoarthritis Index
  • SF-36 36-Item Short Form Health Survey
  • VAS score was assessed at the day of the last infusion, both groups showed a significant decrease in comparison with basal values even if a higher significant difference was observed in the sodium neridronate group ( FIG. 2 ).
  • the comparison between groups at the day of the last infusion showed a significant greater decrease in the group of patients treated with sodium neridronate (p ⁇ 0.001).
  • the sodium neridronate group showed a further significant pain improvement with a VAS score which fell to 9.4 ⁇ 10.8 (p ⁇ 0.001 vs both T0 and T1 values). Also, other pain and functional rating indices showed significant decreases in comparison both with basal values and with placebo treated patients (Table 2).
  • sodium neridronate can be effectively used for reducing pain symptoms in patients with OA having basal VAS (greater than or equal to) 30 mm.
  • a course of sodium neridronate administered intravenously can be effectively used for treating patients with OA, and in particular for reducing mild, moderate or severe pain symptoms, and specifically moderate or severe symptoms, in patients with OA.
  • sodium neridronate can be effectively used for treating patients with OA undergoing acute painful remplises, reducing the extent of bone marrow lesions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
US15/514,651 2014-10-15 2015-10-15 Use of neridronic acid or of its salt for the treatment of osteoarthrosis Abandoned US20170209470A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI20141794 2014-10-15
ITMI2014A001794 2014-10-15
PCT/IB2015/057929 WO2016059594A1 (en) 2014-10-15 2015-10-15 Use of neridronic acid or of its salt for the treatment of osteoarthrosis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/057929 A-371-Of-International WO2016059594A1 (en) 2014-10-15 2015-10-15 Use of neridronic acid or of its salt for the treatment of osteoarthrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/192,094 Continuation US20230233585A1 (en) 2014-10-15 2023-03-29 Use of neridronic acid or of its salt for the treatment of osteoarthrosis

Publications (1)

Publication Number Publication Date
US20170209470A1 true US20170209470A1 (en) 2017-07-27

Family

ID=51904075

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/514,651 Abandoned US20170209470A1 (en) 2014-10-15 2015-10-15 Use of neridronic acid or of its salt for the treatment of osteoarthrosis
US18/192,094 Pending US20230233585A1 (en) 2014-10-15 2023-03-29 Use of neridronic acid or of its salt for the treatment of osteoarthrosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
US18/192,094 Pending US20230233585A1 (en) 2014-10-15 2023-03-29 Use of neridronic acid or of its salt for the treatment of osteoarthrosis

Country Status (32)

Country Link
US (2) US20170209470A1 (da)
EP (1) EP3206694B1 (da)
JP (1) JP6839076B2 (da)
KR (1) KR102591084B1 (da)
CN (2) CN106794190A (da)
AU (1) AU2015332060B2 (da)
BR (1) BR112017006989A2 (da)
CA (1) CA2963066C (da)
CL (1) CL2017000915A1 (da)
CO (1) CO2017003561A2 (da)
CY (1) CY1123420T1 (da)
DK (1) DK3206694T3 (da)
DO (1) DOP2017000096A (da)
EA (1) EA033191B1 (da)
EC (1) ECSP17023093A (da)
ES (1) ES2819186T3 (da)
HR (1) HRP20201475T1 (da)
HU (1) HUE052088T2 (da)
IL (1) IL251421B (da)
LT (1) LT3206694T (da)
MX (1) MX2017004826A (da)
MY (1) MY191481A (da)
NZ (1) NZ730853A (da)
PE (1) PE20170699A1 (da)
PH (1) PH12017500659A1 (da)
PL (1) PL3206694T3 (da)
PT (1) PT3206694T (da)
RS (1) RS60868B1 (da)
SG (1) SG11201702574XA (da)
SI (1) SI3206694T1 (da)
TN (1) TN2017000095A1 (da)
WO (1) WO2016059594A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190328755A1 (en) * 2018-04-30 2019-10-31 Grunenthal Gmbh Methods of treating complex regional pain syndrome (crps) or symptoms comprising administration of neridronic acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20040218A1 (it) * 2004-02-10 2004-05-10 Abiogen Pharma Spa Uso di neridronato sodico per promuovere la neoformazione ossea
EP1755598A4 (en) * 2004-05-06 2008-04-30 Merck & Co Inc METHOD FOR THE TREATMENT OF ARTHRITICAL ILLNESSES IN DOGS
CA2641456A1 (en) * 2006-02-06 2007-08-16 Cypress Bioscience, Inc. Compositions comprising a bisphosphonate and an antifolate
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate

Also Published As

Publication number Publication date
TN2017000095A1 (en) 2018-07-04
CN106794190A (zh) 2017-05-31
HRP20201475T1 (hr) 2020-12-11
EA033191B1 (ru) 2019-09-30
JP6839076B2 (ja) 2021-03-03
JP2017532333A (ja) 2017-11-02
IL251421A0 (en) 2017-05-29
EP3206694A1 (en) 2017-08-23
CY1123420T1 (el) 2021-12-31
ECSP17023093A (es) 2017-06-30
SG11201702574XA (en) 2017-04-27
SI3206694T1 (sl) 2020-11-30
EA201790531A1 (ru) 2017-08-31
LT3206694T (lt) 2020-11-25
PT3206694T (pt) 2020-09-22
KR102591084B1 (ko) 2023-10-18
DK3206694T3 (da) 2020-09-21
PH12017500659A1 (en) 2017-10-02
PE20170699A1 (es) 2017-06-03
AU2015332060A1 (en) 2017-04-27
ES2819186T3 (es) 2021-04-15
MX2017004826A (es) 2018-01-24
WO2016059594A1 (en) 2016-04-21
AU2015332060B2 (en) 2018-06-07
BR112017006989A2 (pt) 2018-03-27
CL2017000915A1 (es) 2017-11-10
US20230233585A1 (en) 2023-07-27
RS60868B1 (sr) 2020-11-30
KR20170066438A (ko) 2017-06-14
NZ730853A (en) 2018-06-29
DOP2017000096A (es) 2017-07-31
MY191481A (en) 2022-06-28
IL251421B (en) 2022-05-01
CA2963066C (en) 2023-12-05
CO2017003561A2 (es) 2017-09-11
CA2963066A1 (en) 2016-04-21
EP3206694B1 (en) 2020-07-08
HUE052088T2 (hu) 2021-04-28
CN111939164A (zh) 2020-11-17
PL3206694T3 (pl) 2020-12-28

Similar Documents

Publication Publication Date Title
DE60009697T2 (de) Verwendung von 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie
US20230233585A1 (en) Use of neridronic acid or of its salt for the treatment of osteoarthrosis
AU2022202148B2 (en) Methods for treating heterotopic ossification
KR20090034810A (ko) 멜라토닌 효능제 치료
US20220305017A1 (en) Compositions and methods for the treatment of estrogen-dependent disorders
JP6986521B2 (ja) 頭痛の予防的治療のためのカルバメート化合物の使用
TW202339731A (zh) 用於治療進行性纖維化間質性肺病之新穎口服醫藥組合物及劑量療法
Mochizuki et al. Safety and efficacy of zoledronic acid treatment with and without acetaminophen and eldecalcitol for osteoporosis
US7429573B2 (en) Method for increasing the bone mineral density and bone micro-architecture or connectivity of a mammal using N-acylated glucosamines
Fava et al. Single Nightly Administration of Ketoprofen (Orudis®) and Indomethacin Suppositories in the Management of Osteoarthritis: A Double-Blind Trial
JP6414727B2 (ja) 関節疾患の治療予防剤
Patel et al. Treatment of Elephantiasic Pretibial Myxedema With Rituximab Therapy
WO2022089544A1 (zh) Bzp在治疗心脑缺血性疾病中的应用
UA137435U (uk) Спосіб лікування остеоартрозу при супутньому гіпотиреозі
HUME KENDALL et al. CONTROL OF MORNING STIFFNESS IN RHEUMATOID ARTHRITIS BY HIGH SALICYLATE DOSAGE: PRELIMINARY REPORT
JPWO2009025091A1 (ja) 線維筋痛症治療用医薬組成物
SULLIVAN Even After Hip Fracture, Many Patients Not Told the ‘O’Word
UA100158U (uk) Спосіб лікування псоріазу, асоційованого з кардіометаболічними порушеннями

Legal Events

Date Code Title Description
AS Assignment

Owner name: ABIOGEN PHARMA SPA, ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VARENNA, MASSIMO;REEL/FRAME:042172/0365

Effective date: 20170404

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STCV Information on status: appeal procedure

Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER

STCV Information on status: appeal procedure

Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED

STCV Information on status: appeal procedure

Free format text: APPEAL READY FOR REVIEW

STCV Information on status: appeal procedure

Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS

STCV Information on status: appeal procedure

Free format text: BOARD OF APPEALS DECISION RENDERED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION